NEW YORK (GenomeWeb) – Clinical Genomics Technologies announced today that it has completed a $26 million financing round.
The company said it will use the proceeds from the financing to commercialize Colvera, its liquid biopsy test for earlier detection of recurrent colorectal cancer, and to advance Colvera for use in CRC screening.